NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102.1 USD | +1.51% |
|
+5.65% | +2.14% |
| 05-16 | Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15 | DP |
| 05-16 | Novartis: presents results of tender offer for MorphoSysy | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 48.96B 66.63B | Sales 2025 * | 50.79B 69.12B | Capitalization | 210B 286B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.42B 14.18B | Net income 2025 * | 11.92B 16.22B | EV / Sales 2024 * | 4.54 x |
| Net Debt 2024 * | 12.44B 16.93B | Net Debt 2025 * | 11.34B 15.44B | EV / Sales 2025 * | 4.36 x |
| P/E ratio 2024 * |
20.1
x | P/E ratio 2025 * |
17.2
x | Employees | 76,057 |
| Yield 2024 * |
3.51% | Yield 2025 * |
3.65% | Free-Float | 85.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novartis AG
More recommendations
More press releases
More news
| 1 day | +1.51% | ||
| 1 week | +5.65% | ||
| Current month | +5.30% | ||
| 1 month | +9.08% | ||
| 3 months | +2.04% | ||
| 6 months | +10.30% | ||
| Current year | +2.14% |
1 week
100.39
102.44
1 month
90.24102.44
Current year
90.24109.00
1 year
90.24109.00
3 years
72.98109.00
5 years
68.65109.00
10 years
66.35109.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 04-12-31 | |
| Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
| Chairman | 68 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 102.1 | +1.51% | 200 |
| 24-05-15 | 100.6 | -1.35% | 2,551 |
| 24-05-13 | 102 | +0.01% | 52,370 |
| 24-05-10 | 102 | +5.49% | 47,189 |
| 24-05-09 | 96.68 | -2.87% | 492 |
Delayed Quote OTC Markets, May 17, 2024 at 11:42 am
More quotes
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
102.9
USD
Average target price
108.5
USD
Spread / Average Target
+5.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +8.49% | 169B | |
| -0.52% | 164B |
- Stock Market
- Equities
- NOVN Stock
- NVSEF Stock